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Abstract
Objective—To examine HIV risk behavior and HIV infection among new injectors in Tallinn,
Estonia.
Design and methods—Data from two cross-sectional surveys of injecting drug users (IDUs)
recruited from a syringe exchange program (N = 162, Study 1) or using respondent driven
sampling (N = 350, Study 2). Behavioral surveys were administered; serum samples were
collected for HIV testing. Subjects were categorized into new injectors (injecting ≤ 3 years) and
long-term injectors (injecting > 3 years).
Results—Twenty-eight of 161 (17%, Study 1) and 73/350 (21%, Study 2) of the study subjects
were new injectors. HIV infection was substantial among the newer injectors: HIV prevalence was
50% (Study 1) and 34% (Study 2), and estimated HIV incidence 31/100 PY and 21/100 PY,
respectively. In Study 2, new injectors were more likely to be female and ethnic Estonian and less
likely to be injecting daily compared with long-term injectors. No significant difference was found
among two groups on sharing injecting equipment or reported number of sexual partners.
Conclusions—A continuing HIV epidemic among new injectors is of critical public health
concern. Interventions to prevent initiation into injecting drug use and scaling up HIV prevention
programs for IDUs in Estonia are of utmost importance.
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Introduction
Estonia has a rapidly expanding injecting drug user (IDU) driven HIV epidemic. HIV
infection entered the IDU community in Estonia in early 2000s.1,2 By 2005, the rate of
newly reported HIV cases in Estonia was 467 per million inhabitants, the highest per capita
rate in Eastern Europe, almost twice the rate of 247 per million inhabitants in Russia, which
had the second highest rate in Eastern Europe.3,4 Only limited information on the prevalence
and trends of HIV infection among IDUs in Estonia is available, but it is clear that major
increases in both injecting drug use and HIV among drug injectors have occurred over the
last decade.
Similar to other Newly Independent States (NISs) of the former Soviet Union, Estonia has
experienced major political, economic and social changes over the last 15 years. Economic
displacement and the disruption of personal, domestic and inter-community networks, have
fueled several overlapping epidemics: increased violence, high-risk sexual behavior,
substance abuse and infectious diseases (HIV, sexually transmitted diseases, tuberculosis).
5,6 This has lead to large increases in morbidity and mortality.7 There has been a dramatic
growth in the extent of drug injecting in Estonia since late 1990.1
Recent initiates into illicit drug injection (new injectors) create special problems for HIV
prevention. First, new injectors may increase the size of the local IDU population, increasing
the need for prevention and treatment services. Second, new injectors may not self identify
as IDUs, may not fully appreciate the need to protect themselves against HIV and other
blood-borne diseases, and may find HIV prevention and drug services difficult to access.
Many, though not all, studies have found higher rates of injecting risk behavior and blood-
borne infections among new injectors.8–10 Cohort studies have shown very high incidence
of hepatitis C infection among recent initiates to injecting.11,12
Previous studies of HIV among IDUs in Estonia have examined prevalence and risk
behavior among the samples as a whole and by demographic subgroups. In this report, we
examine levels of risk behavior and HIV infection among new injectors from two studies
conducted in Tallinn, Estonia in 2004 and 2005.
Methods
Two cross-sectional studies were designed to assess the prevalence of HIV and risk behavior
among IDUs in Estonia. Detailed descriptions of the studies are provided elsewhere.13,14 In
both the studies, current IDUs were recruited for an interviewer-administered risk behavior
survey covering demographics, drug use history, and HIV risk behavior, and biological
sample collection for HIV testing.
Study 113 was conducted in 2004 and recruited a convenience sample of 162 IDUs from two
syringe exchange projects in Tallinn. Eligibility criteria included reporting injecting drugs
within past 90 days, and age 18 years or older. A questionnaire was administered by a
trained interviewer, with questions on injecting and sexual behavior risk behaviors within
last 90 days. Venous blood was collected from participants and tested for the presence of
HIV antibodies using commercially available test kits (HIV-1/HIV-2 III Plus from Abbott
Laboratories (Abbott Park, IL, USA) at the State HIV/AIDS reference laboratory.
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Study 214 was conducted in Tallinn in 2005, and recruited 350 IDUs using respondent
driven sampling (RDS).15,16 Eligible participants reported injecting drugs within past 28
days and were aged 18 or older. A structured questionnaire was administered by a trained
interviewer, with questions on injecting and sexual behavior risk behaviors with in the last
28 days. Dried blood spot specimens were collected and tested for HIV antibodies using
GACELISA, reactive specimens were confirmed using anti-HIV GACPAT immunoassay,
with confirmatory testing conducted on discordant results using the HIV Blot 2.2 Western
Blot assay (AbbotMurex). The testing was undertaken at the UK Health Protection Agency.
Of note, assays used in both studies for detecting antbodies to HIV had high sensitivity and
specificity.17–19
The wording in questionnaires was exactly the same for key variables (gender, ethnicity, age
at IDU initiation) in both studies, though the time frame of measurement for recent drug use
and risk behavior differed (last 90 days in Study 1 and last 28 days in Study 2). Subtraction
of age at first injection from current age gave a measure of the number of years injecting.
We defined ‘new injectors’ in each survey wave as persons who reported their first injection
as occurring within 3 years of the study interview. For calculating time since first injection,
we assigned persons who had first injected at their current age to have been injecting for 6
months, persons who first injected in the previous year to have been injecting for 1 year,
persons who had first injected 2 years prior to their current age to have been injecting for 2
years, and persons who had first injected 3 years prior to their current age to have been
injecting for 3 years.
We then estimated HIV incidence among new injectors using the following assumptions: (i)
all of them were HIV seronegative when they began injecting; (ii) the HIV seropositives
became infected at the midpoint between beginning to inject and the time of blood sample
collection and (iii) no HIV seropositives are lost to AIDS or other causes among the new
injectors.
The time at risk for HIV seronegative new injectors is the total time from first injection to
the time of the interview. The estimated HIV incidence rate was the number of HIV
seropositive new injectors divided by the sum of the time at risk for the HIV seropositive
new injectors (one-half total time from beginning to inject to time of interview) and the time
at risk for the HIV seronegative new injectors (total time from beginning to inject to time of
interview).20
Statistical analysis
Risk behaviors and characteristics were compared between the two groups of IDU (new and
long-term injectors). Pearson's χ2-tests were used for categorical variables and t-tests with
equal variance for continuous variables. RDS analysis Tool v. 5.0.116,21 was used to weight
the sample to control for differences in network size and homophily (the principle that
contact between similar people occurs at a higher rate than among dissimilar people22) to
provide population-based estimates of the characteristics of IDU (Study 2 only).
In order to facilitate comparisons with Study 1, the Study 2 data presented are the observed
values for the subjects.
Ethics
Ethical approval was obtained from the Ethics Review Board of the University of Tartu
(Studies 1 and 2), and from the Riverside Research Ethics Committee, UK (Study 2).
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Results
Table 1 presents socio-demographic and drug use characteristics of subjects for both studies.
In Study 1 (convenience sample, N = 162) no significant differences were found among new
and long-term injectors with the exception that new injectors were younger at the time of the
survey and fewer of them began injecting at very young ages (age at IDU initiation ≤16
years, 18% among new injectors versus 48% among long-term injectors, P = 0.006). In
Study 2 (respondent driven sample, N = 350) new injectors were also younger at the time of
the survey and fewer had begun injecting at very young ages (age at IDU initiation ≤16
years 37% versus 52%, P = 0.03). The new injectors in Study 2 were more likely to be
female (26% versus 14%, P = 0.02), ethnic Estonian (22% versus 12%, P = 0.02) and less
likely to inject daily than long-term injectors (22% versus 42%, P = 0.002).
In order to facilitate comparisons with Study 1, Study 2 data presented in Table 2 are the
observed values for the subjects, unadjusted for recruitment biases. This has the effect of
treating Study 2 as a convenience sample, similar to Study 1. Recruitment biases were
explored in Study 2 sample using RDSAT to adjust for differences in network size and for
homophily.21 Following adjustment, the population estimates were generally quite similar to
the observed values. All observed sample proportions fell within the 95% confidence
intervals of the RDS adjusted population estimates with two exceptions: slightly over
estimating the proportion of daily injectors among new injectors, and the proportion of IDU
with more than one sexual partner in the last 12 among long-term injectors (Table 2).
Table 2 presents HIV prevalence among new and long-term injectors in both the studies and
the estimated HIV incidence among new injectors in both studies. HIV prevalence was high
(∼50%) among both new and long-term injectors, and the differences between new and
long-term injectors were not statistically significant in either study. Estimated HIV
incidence was also high (>20/100 person-years at risk) among new injectors, and the
difference between the studies was not statistically significant (P = 0.27).
In both studies, injection and sexual risk behaviors were similar among new and long-term
injectors. The percentages of subjects reporting injection and sexual risk behaviors were
high, 30–40% reporting receptive sharing of needles and syringes within 90 and 28 days,
respectively, and 40–60% reporting more than one sexual partner in the previous 12 months.
Discussion
Main findings
Both studies found new drug injectors in Tallinn to be primarily young, Russian speaking
and male. Both found ∼20% of current injectors to be new injectors (that is, injecting for
less than 3 years) and generated high estimates of HIV prevalence (between 34 and 50%)
among new injectors, as well as high estimated HIV incidence between 21 and 31 per 100
person years at risk.
What is known already
Other studies also emphasize potentially high prevalence and incidence of HIV among
recently initiated injectors.23,24 Similarly, studies of hepatitis C transmission have generated
high estimates of incidence among recently initiated injectors, and show that the risk of
infection acquisition is highest in the early years of injection.11,12,25
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Limitations of this study
Our studies used different recruitment methods. But as two studies give very similar results
despite differences in sampling we have more confidence in the results. Second, alike for
both of the studies the limitations lie in the potential for information bias adherent to
research on illicit drug use and sexual behavior. There is a tendency for individuals to avoid
negative evaluations and project a positive view of themselves by providing self reports on
behaviors that are socially desirable.26 Third, the selective, constructive process of
remembering makes self-reporting subject to memory biases.27 To diminish potential biases
of self-reporting, respondents under the immediate influence of drug and/or alcohol were
excluded from the study. In addition, respondents were anonymous, and unlinked interviews
were held with trained interviewers in a familiar environment.
What this study adds
Our findings emphasize the critical importance of HIV prevention interventions targeting
recently initiated injectors. In many settings, younger and new injectors may have less
access to HIV prevention and helping services. They may also have less access to HIV
prevention capacity and expertise.28,29 At initiation particularly, new injectors may be
reliant upon older more experienced injectors for assistance with injection, and while this
provides an opportunity of risk regarding the shared use of equipment it is also an
opportunity for peer education.30 Interventions targeting new injectors with peer-
interventions providing information, enhancing risk-reduction skills, and motivating
behavior change through peer education training can lead to reduced injection risk
behaviours.31
While we do not have data on the numbers of persons leaving the active drug injecting
population through death or ceasing to inject), we note the substantial proportion of current
injectors who are recent initiates in both study samples. We also found that new injectors
were of older ages at initiation than long-term injectors. While studies have shown a
decreasing age at initiation in many Eastern European countries, this tendency may have
slowed or even reversed in some countries.32 Some studies suggest that an older age at
initiation is associated with fewer or less severe drug-related problems.33,34
Finally, we emphasize the critical importance of HIV prevention coverage among IDUs,
especially new injectors. In Tallinn, the estimated number of injection drug users was ∼10
000 by the end of 2004.35 In 2005, seven syringe exchange programs were operating with
approximately 230 000 syringes exchanged in Tallinn, and about 90 patients were receiving
methadone substitution treatment (Trummal A, personal communication). Other cities
characterized by high HIV prevalence in Eastern Europe also indicate potentially inadequate
levels of HIV coverage among IDUs.36 The scaling up of HIV prevention for IDUs in
Estonia is of utmost importance. At the same time, there is a need for the scaling up of
antiretroviral HIV treatment to reduce infectiousness and transmission behavior among HIV
positive IDUs, low threshold access to drug treatment, and interventions designed to prevent
or delay initiation to injection.
Additionally and especially given the high prevalence of HIV in the IDU population there is
a need for interventions to reduce the risk of HIV transmission from IDUs to non-injecting
sexual partners.37 While reaching these groups prior to exposure presents challenges, further
research is necessary to identify the characteristics associated with variability in infection
rates and time to infection in order to inform tailoring of existing harm-reduction strategies.
Large-scale implementation or programs known to reduce HIV risk behavior among IDUs
(community outreach, needle and syringe access programs and treatment for drug addiction
(particularly methadone maintenance treatment for heroin addiction) has brought HIV
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epidemics under control in a number of countries, including parts of the US38,39 and
Western Europe.40,41 The data from the new injectors in the studies reported here, however,
suggests that large scale program implementation in Estonia is a matter of great urgency.
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